Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice (Q93531280)
Language:
(P31) (Q13442814)
(P304) 2495-2502
(P433) 25
(P478) 45
(P577) Sunday, January 1, 1989
(P1433) (Q5256275)
(P1476) "Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice" (language: en)
(P2093) F B Weihmuller
M Hadjiconstantinou
J P Bruno
N H Neff
other details